Pelthos Therapeutics financials
$20.92−1.55%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 |
|---|---|
| Revenue | $16.8M |
| Gross profit | $12.8M |
| Gross margin | 76.3% |
| Operating income | -$32.4M |
| Net income | -$43.3M |
| Net margin | −257.9% |
| Diluted EPS | $-23.04 |
| EBITDA | -$30.1M |
| Operating cash flow | -$22.6M |
| Free cash flow | -$22.7M |
| Diluted shares | 1.9M |
Balance sheet
| Period end | Dec 31 |
|---|---|
| Cash & equivalents | $18.0M |
| Short-term investments | $0.00 |
| Total debt | $31.4M |
| Total assets | $130.4M |
| Total liabilities | $91.5M |
| Shareholders' equity | $38.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology